2024-10-26 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis:

**1. Performance Compared to S&P 500 (VOO)**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO).  As of today, LLY's cumulative return is 856.19% while VOO's is 135.48%. This translates to a difference of **720.71%**, which represents the **89.53rd percentile** compared to historical performance.  

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company known for its research and development of innovative medicines.

**2. Recent Price Movement:**

* **Closing Price:** $891.32 (Last Market: $892.61)
* **5-Day Moving Average:** $905.56
* **20-Day Moving Average:** $904.54
* **60-Day Moving Average:** $907.06

The stock is currently trading slightly below its recent moving averages, indicating potential for a slight downward correction. 

**3. Technical Indicators:**

* **RSI:** 51.75 - Indicates a neutral market condition, neither overbought nor oversold.
* **PPO:** -0.17 - Signals a slight bearish momentum.
* **Delta_Previous_Relative_Divergence:** -2.95 - Suggests a short-term downward trend in relative performance.
* **Expected Return:** 96.56% - This is the estimated long-term (2+ years) excess return compared to the S&P 500 assuming a buy-and-hold strategy.

**4. Recent Earnings and Outlook:**

| Date  | EPS  | Revenue   |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings report (2024-08-08) showed a significant increase in EPS and revenue compared to the previous quarter. This suggests a positive trend in the company's performance. 

**5. News and Recent Issues:**

* **Recent Earnings News:**  Positive news articles about the latest earnings report have been published by financial news outlets such as Shacknews.  The earnings beat analyst expectations and provided a positive outlook for future growth.
* **Recent Market Outlook:** The stock has been receiving strong analyst recommendations, with several analysts rating it as a “buy” or “strong buy” based on its strong earnings, pipeline of new drugs, and potential for future growth.
* **Analyst Opinions and Performance Highlights:** FINBOLD reports that analysts are optimistic about LLY's future performance, highlighting its impressive earnings and robust pipeline of innovative products as major catalysts for continued growth. 

**6. Overall Analysis:**

Eli Lilly and Co (LLY) appears to be a strong performer with a compelling track record of outperforming the market. Its recent earnings results have been positive and analysts are optimistic about the company's future prospects. However, the stock is currently trading slightly below its moving averages, potentially indicating a short-term correction.  The strong long-term expected return makes it an attractive option for long-term investors with a high-growth, high-reward portfolio strategy.

**7.  Recommendations:**

* **Long-Term Investors:**  LLY is a strong candidate for long-term investment due to its impressive past performance, robust pipeline, and positive analyst sentiment.
* **Short-Term Traders:** The current market positioning with the stock trading below its moving averages could present an opportunity for short-term traders to enter with caution, using technical analysis to identify potential entry and exit points.

This analysis provides a general overview of LLY's current performance and prospects. It's essential to conduct further research and consult with a financial advisor before making any investment decisions. 
